PhaseBio Pharmaceuticals, Inc. — Revenue by Fiscal Year
4 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/127c4978-86cc-4e89-90c3-99c3db1a3ef2/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2021 | $10.8M | 2021-01-01 – 2021-12-31 | evidence 0001169245-22-000028 |
| FY 2020 | $320.0k | 2020-01-01 – 2020-12-31 | evidence 0001169245-21-000024 |
| FY 2019 | $2.4M | 2019-01-01 – 2019-12-31 | evidence 0001169245-20-000043 |
| FY 2018 | $668.0k | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-009364 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
PhaseBio Pharmaceuticals, Inc. — all facts · Net Income · Operating Income